Abstract
Gene therapy through viral vectors has great potential, and is already being used in clinical protocols in humans. Third-generation adenoviral vectors (high-capacity, gutless, or helper-dependent-HD) are safer than first-generation vectors, but the main concern limitation for their large-scale application is to obtain contamination-free helper virus particles. Adenoviruses of phylogenetic…